Elsunersen demonstrated placebo-adjusted seizure reduction from baseline of 77% (p=0.015)71% of elsunersen-treated patients achieved >50% ...
Praxis Precision Medicines, Inc. PRAX shares are trading higher Monday after the company announced positive results from the ...
Praxis Precision Medicines, Inc.: two NDAs, relutrigine priority review, and DEE pipeline catalysts through 2027. Click for ...
Praxis Precision Medicines (PRAX) recently drew attention after the FDA accepted its New Drug Application for relutrigine with priority review for SCN2A and SCN8A developmental and epileptic ...
View Praxis Precision Medicines, Inc. PRAX stock quote prices, financial information, real-time forecasts, and company news from CNN.
FDA assigned PDUFA target action date of September 27, 2026BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: ...
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. If you are wondering whether ...
Having already claimed a win for the phase 2 study of its seizure drug, Praxis Precision Medicines is hoping fresh efficacy data will form the backbone of an approval application for the sodium ...
Deerfield Management Company increased its PRAX stake by 62,500 shares in the fourth quarter; the estimated transaction value was $11.64 million based on quarterly average prices. Meanwhile, the ...
Praxis Precision Medicines' New Drug Application for relutrigine will receive priority review by the Food and Drug Administration. The clinical-stage biopharmaceutical company said Monday that the FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results